ReShape Lifesciences (Formally known as EnteroMedics)
2800 Patton Road
261 articles with ReShape Lifesciences (Formally known as EnteroMedics)
ReShape Lifesciences Inc. announced the Company has commenced site initiation training for the first clinical trial site that will participate in the multi-center trial of the ReShape VestTM to support CE Mark approval.
ReShape Lifesciences Inc. (Nasdaq:RSLS), today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,241,382 shares of its common stock.
ReShape Lifesciences Expands Intra-gastric Balloon Business to Include Brigham and Women's Hospital in Boston
ReShape Lifesciences Inc. announced the successful implant of the first ReShape Balloon™ at the Brigham and Women's Hospital in Boston, MA.
The company has had an abstract accepted by the scientific committee of the 23rd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).
ReShape Lifesciences Inc. announces that the United States Patent and Trademark Office ("USPTO") has issued an Issue Notification for U.S. Patent Number 10010441 entitled "Gastric Restriction Device for Treating Obesity,"
ReShape Lifesciences Inc. announced that it has entered into definitive agreements with several institutional investors for the purchase of 374,572 shares of its common stock, at a purchase price per share of $3.92
ReShape Lifesciences Inc. announced the formation of the Company's Scientific Advisory Board (SAB)
ReShape Lifesciences Announces New Patent Grant Expanding its Bioelectronic and Neuromodulation Portfolio
Patent is directed to a combination of blocking and stimulating the vagus and celiac nerve branches using specific bioelectronic parameters to treat gastrointestinal disorders, including obesity, diabetes, and various combinations thereof.
ReShape Lifesciences Provides Update on FDA Letter to Health Care Providers Related to Intragastric Balloons
ReShape Lifesciences Inc. provided an explanation and clarifying details to a letter dated June 4, 2018 that the U.S. Food and Drug Administration (FDA) posted on their website addressed to Health Care Providers.
ReShape Lifesciences Inc. announced that its Board of Directors has declared a 1-for-15 reverse stock split of the company's common stock
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company will be exhibiting and participating at Digestive Disease Week (DDW), which is taking place from June 2-5, 2018 at the Walter E. Washington Convention Center in Washington, DC.
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the submission of an application to the Medical Devices Bureau of the Therapeutic Products Directorate in Canada that seeks to amend the Company's existing Canadian medical device license to include distribution of the Company's current generation ReShape Balloon™ and associated accessories.
ReShape Lifesciences Inc. announced that it will host a conference call to discuss financial results for the first quarter 2018 on Monday, May 14, 2018 at 1:30 PM Pacific Time.
ReShape Lifesciences Inc. announced that the ReShape Balloon™ was granted registration by the National Health Regulation Authority (NHRA) in the Kingdom of Bahrain.
ReShape Lifesciences Inc. announced that over 40 surgeons were trained to implant the ReShape BalloonTM during the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2018 /16th World Congress that was held in Seattle from April 11-14, 2018.
Results Showing Improved Glycemic Control with ReShape Lifesciences Neuromodulation in an Obese Rat Model to be Presented at Industry Conference
ReShape Lifesciences Continues Expansion in Middle East with Approval of ReShape Balloon in Saudi Arabia
Initial Stocking Order Received from Dar Al Zahrawi Medical Co LLC, KSA
ReShape has entered into a securities purchase agreement with an institutional investor providing for the purchase and sale in a registered direct offering of shares of series D convertible preferred stock and a warrant to purchase shares of common stock for a purchase price of $6.0 million.
ReShape Lifesciences Inc. reported financial results for the three months and full year ended December 31, 2017.
ReShape vBloc to be Featured at the Bariatric Metabolic Surgery Standardization World Consensus Meeting
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the ReShape vBloc™ product will be discussed during the Bariatric Metabolic Surgery Standardization World Consensus Meeting taking place in New Delhi, India from March 22-24, 2018.